Table 3.
Outcomes Variations in Omalizumab Group
| Omalizumab | |||
|---|---|---|---|
| Pre | Post | p value | |
| Eos (cell/mcl), mean ± SD | 325.8 ± 331.2 | 331.8 ± 293.5 | 0.86 |
| Eos (%), mean ± SD | 4.2 ± 3.6 | 4.4 ± 3.5 | 0.94 |
| Neutr (cell/mcl), mean ± SD | 4760 ± 2189 | 4498 ± 1478 | 0.76 |
| Neutr (%), mean ± SD | 58.1 ± 12.6 | 56.6 ± 7.8 | 0.69 |
| IgE tot (kU/L), mean ± SD | 586.8 ± 910.3 | 578 ± 621 | 0.91 |
| ACT, mean ± SD | 14.7 ± 3.7 | 21.9 ± 2 | <0.0001 |
| ACQ, mean ± SD | 3 ± 0.7 | 1.8 ± 0.7 | <0.0001 |
| AQLQ, mean ± SD | 4.8 ± 0.9 | 5.5 ± 0.8 | 0.0003 |
| Hospitalizations in the last year, mean ± SD | 0.3 ± 0.6 | 0.04 ± 0.2 | 0.012 |
| Exacerbations in the last year, mean ± SD | 4.1 ± 2.1 | 0.5 ± 0.6 | <0.0001 |
| FEV1 (L), mean ± SD | 1.9 ± 0.8 | 2.2 ± 1 | 0.0006 |
| FEV1 (%), mean ± SD | 65.3 ± 13.3 | 73.7 ± 16.5 | <0.0001 |
| FVC (L), mean ± SD | 3 ± 1.1 | 3.2 ± 1.3 | 0.15 |
| FVC (%), mean ± SD | 82.8 ± 15.9 | 85.8 ± 17.3 | 0.09 |
| FEV1/FVC, mean ± SD | 69.1 ± 12.3 | 69.3 ± 10.6 | 0.35 |
| ICS (mcg/die), mean ± SD | 798.8 ± 237 | 873.7 ± 345.6 | 0.21 |
| OCS (mg/die), mean ± SD | 2.4 ± 4.7 | 0.6 ± 1.7 | 0.006 |
| LAMA, n (%) | 27 (50) | 23 (42.6) | 0.56 |
| LTRA, n (%) | 33 (61) | 29 (53.7) | 0.56 |
| Theophylline, n (%) | 5 (9.3) | 0 (0) | 0.056 |